1. Maznei kova V. Vaginal candidiasis treatment protocols using miconazole and fluconazde. Akush ginekol (sofila). 2003; 42: 30-40.
2. Matar MJ, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. Correlation between ETest, Disk Diffusion, and Microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother. 2003; 47(5): 1647-51. doi: 10.1128/aac.47.5.1647-1651.2003. [
DOI:10.1128/AAC.47.5.1647-1651.2003]
3. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(5): 503-35. doi: 10.1086/596757. [
DOI:10.1086/596757]
4. Ahmad A, Khan AU. Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur J Obstet Gynecol Reprod Biol. 2009; 144(1): 68-71. doi: 10.1016/j.ejogrb.2008.12.020. [
DOI:10.1016/j.ejogrb.2008.12.020]
5. Cherif A, Khrouf N, Jabnoun S, Mokrani C, Amara MB, Guellouze N, et al. Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patentductus arteriosus. Pediatrics. 2008; 122: 1256-61. doi: 10.1542/peds.2008-1780. [
DOI:10.1542/peds.2008-1780]
6. World Health Organization. WHO Model List of Essential Medicines. 20th ed. 2017.
7. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed. Pennsylvania:Wayne, PA. 2008.
8. Badiee P, Alborzi A, Shakiba E, Ziyaeyan M, Rasuli M. Molecular Identification and in-vitro susceptibility of Candida albicans and C. dubliniensis Isolated from Immunocompromised Patients. Iranian Red Crescent Medical Journal. 2009; 11(4): 391-97.
9. Richter S, Rudolph P. Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases. Clin Microbiol. 2005; 43(5): 2155-62. doi: 10.1128/JCM.43.5.2155-2162.2005. [
DOI:10.1128/JCM.43.5.2155-2162.2005]
10. Mirhendi SH, Makimura K, Shidfar MR Hosseinpour L. Identification and Frequency of Candida Patients isolates by Chromagar candida method. Avicenna Journal of clinical Medicine. 2007; 13(4):11-15.
11. Aghamirian M, keshavarz D, Jahani Hashemi H, sadeghi Qazvini M. Agents associated with candida vulvovaginitis in women referred to health centers in Qazvin. J Qazvin Univ Med Sci. 2007; 11(3): 35-9.
12. Nasrollahi Omran AA, Vakilli L, Jafarpur M. Determination of Vaginal Candidiasis in Women Referred to Shahid Rajaei hospital in Tonekabon(2009-2010). Medical Laboratory Journal. 2011; 5(1): 1-7.
13. Jamilian M, Mashadi E, Sarmadi F, Banijamali M, Farhadi E, Ghanatpishe E. Frequancy of vulvovaginal Candidiasis species in nonpregnant 15-50 years old women in spring 2005 in Arak. J Arak Uni Med Sci. 2007; 10(2): 7-14.
14. Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis. N Engl j Med. 2004; 351: 876-83. [
DOI:10.1056/NEJMoa033114]
15. Nouraei S, Amir Ali Akbari S, Jorjani M, Alavi Majd HM, frakhteh A, Ghaforian A, et al. Comparison Between the Effect of Fluconazole and Oral Protexin Combination and Fluconazole on the Treatment of Vulvovaginal Candidiasis. J Arak Uni Med Sci. 2013; 16(4):62-73.
16. Nowrozi H, Kazemi A. The Effect of Ultraviolet (UV) Radiation Duration on Drug Susceptibility Testing of Rhizopus spp. to Amphotericin B, Itraconazole and Fluconazole. JSSU. 2014; 22(1): 850-57.
17. Nozari SH, Haydari Kohan F, Ashrafi Khozani M, Ahmadi F, Ghasemi Z, Nami S, et al. Comparison of Antifungal Effect of Fluconazole alone and in Combination with Nanosilver Particles against Candida spesies Isolated from Chronic Candidal Vulvovaginitis. Razi Journal of Medical Science. 2012; 18(93): 8-14.